Last reviewed · How we verify
FC084CSA tablets
At a glance
| Generic name | FC084CSA tablets |
|---|---|
| Sponsor | FindCure Biosciences (ZhongShan) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors (PHASE1, PHASE2)
- A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FC084CSA tablets CI brief — competitive landscape report
- FC084CSA tablets updates RSS · CI watch RSS
- FindCure Biosciences (ZhongShan) Co., Ltd. portfolio CI